“Clinical characteristics, symptoms, management and health outcomes in 8,598 pregnant women diagnosed with COVID-19 compared to 27,510 with seasonal influenza in France, Spain and the US: a network cohort analysis”

Lana Yin Hui Lai, Asieh Golozar, Anthony G. Sena, Andrea V. Margulis, Nuria de Haro, Paula Casajust, Neus Valveny, Albert Prats‐Uribe, Evan Minty, Waheed‐Ul‐Rahman Ahmed, Thamir M. Alshammari, Daniel R. Morales, Heba Alghoul, Osaid Alser, Dalia Dawoud, Lin Zhang, Jose Posada, Nigam H. Shah, Clair Blacketer, Carlos Areia, Vignesh Subbian, Fredrik Nyberg, Jennifer C. E. Lane, Marc A. Suchard, Mengchun Gong, Martina Recalde, Jitendra Jonnagaddala, Karishma Shah, Elena Roel, David Vizcaya, Stephen Fortin, Ru-fong Joanne Cheng, Christian Reich, George Hripcsak, Peter Rijnbeek, Patrick Ryan, Kristin Kostka, Talita Duarte‐Salles, Daniel Prieto‐AlhambramedRxiv 2020 · DOI

Introduction

Early in the COVID-19 pandemic, clinical data regarding the impact of the virus on pregnant women was largely restricted to small case series or single-center reports. This created a significant knowledge gap for clinicians attempting to assess the relative risks of COVID-19 compared to other respiratory threats, such as seasonal influenza. This study addresses this gap by utilizing a large-scale multinational network cohort analysis to describe the comorbidities, symptoms, medication use, and 30-day outcomes of 8,598 pregnant women with COVID-19, using 27,510 pregnant women with influenza as a historical benchmark.

Methodology: The Power of Network Analytics

The researchers conducted a federated analysis through the Observational Health Data Sciences and Informatics (OHDSI) network. This approach allowed for the analysis of data from six major databases across France, Spain, and the United States without moving sensitive individual patient data across borders.

By mapping data to the OMOP Common Data Model (CDM), the study ensured that clinical definitions—such as "pneumonia" or "preterm labor"—were harmonized across diverse electronic health records (EHR) and insurance claims databases. The COVID-19 cohorts (diagnosed between January and June 2020) were compared against a historical cohort of pregnant women diagnosed during the 2017-2018 influenza season.

Clinical Presentation and Diagnostic Markers

While common respiratory symptoms like cough and fever are shared by both viruses, the study identified specific clinical "fingerprints" that distinguish COVID-19 in pregnant populations. Anosmia (loss of smell) and dyspnea (shortness of breath) were significantly more prevalent in women with COVID-19 than in those with influenza. These symptoms serve as critical diagnostic markers for differential diagnosis in clinical settings.

Furthermore, the study identified specific comorbidities associated with increased severity. Pregnant women who required hospitalization for COVID-19 exhibited a higher prevalence of pre-existing renal impairment (5.1% in hospitalized vs. 2.2% in diagnosed) and anemia (21.3% in hospitalized vs. 15.5% in diagnosed) compared to those who were diagnosed but not hospitalized.

Inpatient Management and Medication Use

The analysis revealed a high degree of polypharmacy in the management of hospitalized pregnant women. Despite limited evidence regarding the benefit-risk profiles of many treatments for this specific population at the time, a wide array of medications was utilized:

  • Systemic corticosteroids: 29.6%
  • Enoxaparin: 24.0%
  • Immunoglobulins: 21.4%
  • Famotidine: 20.9%
  • Azithromycin: 18.1%
  • Hydroxychloroquine: 5.4%

The researchers noted that some treatments, particularly corticosteroids, may have been administered for pregnancy-related indications (such as accelerating fetal lung development) rather than as a direct treatment for COVID-19.

Comparative Outcomes: COVID-19 vs. Influenza

One of the most significant findings of the study is the disconnect between mortality and morbidity. While the fatality rate for COVID-19 in pregnant women was negligible (fewer than 5 deaths per database), the risk of severe complications was substantially higher than that of seasonal influenza.

Maternal Complications

Women with COVID-19 experienced significantly higher rates of organ-level complications compared to the influenza cohort:

  • Pneumonia: 12.0% vs. 2.7%
  • Acute Respiratory Distress Syndrome (ARDS): 4.0% vs. 0.3%
  • Sepsis: 2.1% vs. 0.7%

Pregnancy and Neonatal Outcomes

COVID-19 also appeared to impact delivery and birth outcomes more severely than influenza:

  • Cesarean Section: 4.4% vs. 3.1%
  • Preterm Delivery: 0.9% vs. 0.5%

In specific datasets, such as the IQVIA-OpenClaims database, the risk of hospitalization for COVID-19 (29.6%) was nearly double that of influenza (16.9%).

Discussion and Limitations

While this study provides a robust multinational perspective, it is subject to the limitations of real-world data. Symptoms like anosmia may be under-reported in electronic health records compared to standard vitals. Additionally, the implementation of universal screening in many US hospitals likely captured asymptomatic cases, which may have diluted the observed severity in the "diagnosed" cohort.

In conclusion, while the fatality rate for COVID-19 in pregnancy remains low, the virus carries a significantly higher burden of morbidity and pregnancy-related complications than seasonal influenza. These findings underscore the importance of vigilant monitoring and the need for further research into the long-term health of both mothers and children exposed to the virus in utero.

Summary updated

Abstract

ABSTRACT OBJECTIVES To describe comorbidities, symptoms at presentation, medication use, and 30-day outcomes after a diagnosis of COVID-19 in pregnant women, in comparison to pregnant women with influenza. DESIGN Multinational network cohort SETTING A total of 6 databases consisting of electronic medical records and claims data from France, Spain, and the United States. PARTICIPANTS Pregnant women with ≥ 1 year in contributing databases, diagnosed and/or tested positive, or hospitalized with COVID-19. The influenza cohort was derived from the 2017-2018 influenza season. OUTCOMES Baseline patient characteristics, comorbidities and presenting symptoms; 30-day inpatient drug utilization, maternal complications and pregnancy-related outcomes following diagnosis/hospitalization. RESULTS 8,598 women diagnosed (2,031 hospitalized) with COVID-19 were included. Hospitalized women had, compared to those diagnosed, a higher prevalence sof pre-existing comorbidities including renal impairment (2.2% diagnosed vs 5.1% hospitalized) and anemia (15.5% diagnosed vs 21.3% hospitalized). The ten most common inpatient treatments were systemic corticosteroids (29.6%), enoxaparin (24.0%), immunoglobulins (21.4%), famotidine (20.9%), azithromycin (18.1%), heparin (15.8%), ceftriaxone (7.9%), aspirin (7.0%), hydroxychloroquine (5.4%) and amoxicillin (3.5%). Compared to 27,510 women with influenza, dyspnea and anosmia were more prevalent in those with COVID-19. Women with COVID-19 had higher frequency of cesarean-section (4.4% vs 3.1%), preterm delivery (0.9% vs 0.5%), and poorer maternal outcomes: pneumonia (12.0% vs 2.7%), ARDS (4.0% vs 0.3%) and sepsis (2.1% vs 0.7%). COVID-19 fatality was negligible (N<5 in each database respectively). CONCLUSIONS Comorbidities that were more prevalent with COVID-19 hospitalization (compared to COVID-19 diagnosed) in pregnancy included renal impairment and anemia. Multiple medications were used to treat pregnant women hospitalized with COVID-19, some with little evidence of benefit. Anosmia and dyspnea were indicative symptoms of COVID-19 in pregnancy compared to influenza, and may aid differential diagnosis. Despite low fatality, pregnancy and maternal outcomes were worse in COVID-19 than influenza. WHAT IS ALREADY KNOWN ON THIS TOPIC Compared to non-pregnant women of reproductive age, pregnant women are less likely to experience typical COVID-19 symptoms, such as fever and myalgia. Obesity, high maternal age, and comorbid hypertension and diabetes are risk factors for severe COVID-19 among pregnant women. Despite relatively high rates of pneumonia and need for oxygen supplementation, fatality rates in pregnant women with COVID-19 are generally low (<1%). WHAT THIS STUDY ADDS Although not often recorded, dyspnea and anosmia were more often seen in pregnant women with COVID-19 than in women with seasonal influenza, in 6 databases from 3 countries (US, France, Spain). Renal impairment and anemia were more common among hospitalized than diagnosed women with COVID-19 during pregnancy. Despite limited data on benefit-risk in pregnancy, a large number of medications were used for inpatient management of COVID-19 in pregnant women: approximately 1 in 3 received corticosteroids (some may have been given for a pregnancy-related indication rather than for COVID-19 treatment), 1 in 4 enoxaparin, and 1 in 5 immunoglobulin, famotidine and azithromycin. Compared to influenza, there was a higher frequency of pregnancy-related complications (cesarean section and preterm deliveries), as well as poorer maternal outcomes (pneumonia, acute respiratory distress syndrome, sepsis, acute kidney injury, and cardiovascular and thromboembolic events) seen in pregnant women diagnosed with COVID-19.
BibTeX
@misc{lai2020clinical,
  author = {Lana Yin Hui Lai and Asieh Golozar and Anthony G. Sena and Andrea V. Margulis and Nuria de Haro and Paula Casajust and Neus Valveny and Albert Prats‐Uribe and Evan Minty and Waheed‐Ul‐Rahman Ahmed and Thamir M. Alshammari and Daniel R. Morales and Heba Alghoul and Osaid Alser and Dalia Dawoud and Lin Zhang and Jose Posada and Nigam H. Shah and Clair Blacketer and Carlos Areia and Vignesh Subbian and Fredrik Nyberg and Jennifer C. E. Lane and Marc A. Suchard and Mengchun Gong and Martina Recalde and Jitendra Jonnagaddala and Karishma Shah and Elena Roel and David Vizcaya and Stephen Fortin and Ru-fong Joanne Cheng and Christian Reich and George Hripcsak and Peter Rijnbeek and Patrick Ryan and Kristin Kostka and Talita Duarte‐Salles and Daniel Prieto‐Alhambra},
  title = {{“Clinical characteristics, symptoms, management and health outcomes in 8,598 pregnant women diagnosed with COVID-19 compared to 27,510 with seasonal influenza in France, Spain and the US: a network cohort analysis”}},
  year = {2020},
  doi = {10.1101/2020.10.13.20211821},
  howpublished = {medRxiv},
}
Figure